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HormOn asYs are beingdeoped n the rty to deect ecm r mkers in nOnClIniCaI populations.
Epidem is inc ly uwng these ass to mprve thepion wih which dise pses and expoes can
bdefined. Thisgro nboyfmre Iogyr esahlghdegreeofo betwh themaey developer
and the as user. Mk draw our e nce ina sense hormne for the detection of earl pny via
urinary human chorionic gonadotropin to flstratethese points We concude that this cfborative efort, in addition
to making thiS study possible, has provided rewards.
"But those epidemiologists don't understand the physiologic basis of these
studies," the endocrinologist tells his colleagues. "Those endocrinologists are
lost in detail; they study a few people endlessly," the epidemiologist reports.
Given the wide gulf between these views, can a "marriage"
between epidemiology and endocrinology succeed? Ifthe answer
is in the affirmative, under what conditions is such a union likely
to be successful? What is the likely product ofsuch a union? We
attempt to answer these questions using our experience in a
collaborative effort between endocrinology and epidemiology in
the study of early pregnancy loss. In particular, we describe
conditions under which an assay is likely to be useful to the
epidemiologist as a biomarker in large populations.
Background
Hormone Assays
Prior to the discovery and application ofradioimmunoassays
in the early and mid-1970s, analytic techniques such as colori-
metry, gas-liquid chromataphy, competitive protein binding,
and double isotope dilution methods were employed to measure
hormone concentrations. These tests were either too laborious
or insensitive to be practical for routine monitoring. These
methods were, however, quite useful for measuring changes in
urinary hormone excretion because of the large quantities of
urine that could be easily collected and the higher concentration
of hormones in urine compared to plasma or serum.
With the advent ofthe radioimmunoassay (for which Berson
and Yallow were awarded the Nobel prize), assays became more
sensitive, and it was considered more appropriate to measure
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the active compound in circulation rather than its metabolite in
the excreta. This, then, became the accepted standard in the field
and replaced the use of urinary assays for research purposes.
Subsequendy (1978-1980), urinary and fecal steroid hormone
metabolite monitoring methods were developed in the zoo set-
ting to obtain biological samples without capture and restraint.
These second-generation assays took advantage ofthe improv-
ed technology that had been developed for serum and plasma
assays and applied it to urine and feces (1). More recently, the
recognition ofthe advantages of collecting and analyzing urine
in human populations has renewed interest in this approach (2).
Unlike blood sampling, urine sampling, which is nonintrusive,
can be accomplished in large populations with a high level of
compliance, samples can be collected over a prolonged time
period, and collection requires no special skills or instruments.
Until recently, the assays employed to measure hornones have
been radioimmuno- or radiometric assays applied to small clinic
populations (3). Continued developments in this field have led
to an array of assays that eliminate the need for radioactive
materials, and in some case, obviate the need for a laboratory
(4,5). The combined result of the concentrating effect of the
kidney, the lack of binding proteins in urine, and the water-
soluble nature of the hormone metabolites allows virtually all
assay formats to be applied to unprocessed urine. Although
dipstick kits are available for only a few hormones, more will be
available shortly (6). The end result will be a series of easy-to-
use, sensitive, and specific assays for use in large epidemiologic
populations.
Epidemiology
Until recendy, when sensitive urinary assays became available,
epidemiologists interested in subfecundity and early pregnancy
loss were limited to such indirect measures as the number and
timing of births or the study of spontaneous abortion using
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timing of births or the study of spontaneous abortion using
clinically observable end points. However, it has long been
suspected that clinically recognized fetal loss represents only
a fraction of total postconception loss, although previous
estimates of the magnitude of this loss have varied widely
(7,8). Moreover, pregnancy loss is a relatively crude indicator
of reproductive dysfunction; hormone levels, length of the
luteal phase, and ovulation, if measurable, might provide more
direct indicators of female reproductive health.
Even the study of clinically recognized spontaneous abor-
tion is difficult. The earlier in gestation that a pregnancy is
recognized by a woman or her health-care provider, the
greater the probability that a spontaneous abortion will be
reported. This is further complicated by the fact that women
at high risk of loss, whether on the basis of past history, age,
or symptoms in a current pregnancy, are more likely to seek
early prenatal care. Therefore, losses in these high-risk
groups are more likely to be documented. This form of
selection bias is likely to be present in all epidemiological
studies of clinically recognized pregnancy, regardless of
design.
In addition, there are problems specific to the particular
design used. Case-control studies must rely on self-reported
pregnancy loss, which may be over- or underreported.
Medical record review will minimize overreporting, but
underreporting, particularly if differential, may remain a pro-
blem. Furthermore, retrospective recall of exposures that are
likely to be poorly recalled may be problematic. On the
other hand, cohort studies of recognized pregnancies may
underestimate spontaneous abortion rates, since many losses
occur either before the subject is identified as a cohort
member or between the time the subject is identified and the
interview. For example, spontaneous abortion rates in the
literature, based on retrospectively recalled, self-reported
loss, are 10 to 15% (9,10). In contrast, a recent case-cohort
study found a crude spontaneous abortion rate of only 7.5%
(11).
There is a way out of this dilemma: conduct careful sur-
veillance on a group of women "at risk of pregnancy" and
follow them uniformly to determine pregnancy outcome.
There are several levels at which this surveillance can be car-
ried out. The least sensitive of these methods would be to
distribute home pregnancy kits to study subjects after they
miss a menstrual period. A somewhat more sensitive method
has been used in which women tested their own urine using
home kits for a fraction of each month, whether or not a men-
strual period had been missed (12). Alternatively, one can
detect pregnancies as early as the seventh postconception day
by conducting ongoing surveillance through sensitive urinary
hormone assays carried out by an endocrine laboratory. This
is the option we have chosen.
This choice was made possible by the recent development
of a relatively inexpensive urinary hormone assay (13). Not
only does this assay satisfy the usual laboratory requisites of
sensitivity and specificity, but it also satisfies the conditions
discussed below for successful cooperation between the
laboratory scientist and the epidemiologist. This assay has
successfully been used in one epidemiologic study (14) and
is currently employed in several ongoing studies.
Prerequisites for an Effective
Collaboration between Laboratory
Scientist and Epidemiologist
Conditions on the Assay
It is ofprimary importance that the assay detect an end point
that is both ofepidemiologic and clinical interest. That is, the end
point must be sufficiently common to warrant epidemiologic
study. A rare genetic defect, which might have clinical sig-
nificance, would not be ofgreat epidemiological interest. Con-
versely, the epidemiologist is unlikely to find an assay developed
unless it is clinically useful.
Needs for sensitivity and specificity differ somewhat for the
laboratory scientist and the epidemiologist. The epidemiologist
wants an assay with low false-positive rate (high specificity), for
example, to avoid falsely telling women that they are pregnant.
On the other hand, the epidemiologist, knowing that it is never
possible to detect all pregnancies, may be less concerned about
sensitivity than the laboratory scientist. However, it is important
to both members of the team that the assay be highly reliable.
The assay should be easily usable in multiple laboratories, and
all reagents should be available for a long period oftime. For ex-
ample, when the rabbit that produced the antibody used by Can-
field (13) died, the resulting shortage ofantibody delayed the use
ofradioimmunoassays for studies ofearly pregnancy loss. For-
tunately, a monoclonal antibody that has the desired properties
is now available.
To be useful epidemiologically, an assay should use specimens
or samples that are easily obtainable, such as urine. The collec-
tion method should require a minimum of skill and equipment.
For example, assays on bone marrow or fat tissue are clearly not
useful in large populations. In addition, the assay should not re-
quire large volumes of specimens. For example, the original
human chorionic gonadotropin (hCG) assays required 40 times
the amount of urine now used. Current assays require less than
5 mL of urine, so it is now practical to ask women to store
samples in their home freezers.
The collection procedure should be such that it can be imposed
on subjects for a long time period. Based on only a few samples,
it is not possible to establish "baseline" measurements, or to
assess intrasubject variability. When infrequent events like
pregnancy are under study, even more measurements are re-
quired. Subjects in the Wilcox and Canfield study (13,14) were
required to collect urine for 6 months or until pregnant. A similar
protocol is being followed in current studies. In addition, it is im-
portant that the timing ofspecimen collection and storage not be
too critical. Fortunately, urine collection for hCG and steroid
assays can be done at home, and these assays are not sensitive to
temperature changes or freeze-thaw cycles. In fact, future urine
assays may use a sample adsorbed onto filter paper, which will
not require cold storage at all.
Finally, assay costs should be low enough to make studies in
large populations feasible.
Conditions on Researchers
The distribution ofthe end points assayed in large populations
must be of interest to the laboratory scientist as well as to the
epidemiologist. The study of large populations rather than
144
WHENISA BIOASSAYREADYFOR EPIDEAIIOLOGIC USE? 145
individuals requires thinking in probabilistic and statistical
terms. This frame of reference may be unfamiliar to the
laboratory-based scientist. Conversely, the epidemiologist must
be willing to think about the clinical implications oflaboratory
results, which may be equally unfamiliar. Thus, both members
ofthe team must be willing to invest appreciable amounts oftime
learning about the field of mutual collaboration, so that inter-
pretation of assay findings will be biologically and epidemio-
logically meaningful.
The primary interest of the laboratory scientist may well be
assay development. However, for this collaboration to work, a
laboratory must be set up to perform large numbers ofrepeated
measurements. This involves the development oftechniques for
the meticulous labeling, handling, and storage of large volumes
of samples. For example, a current study being conducted by the
California Department ofHealth Services in collaboration with
the Endocrine Laboratory at the University ofCalifornia at Davis
(the Women's Reproductive Health Study) will require handling
close to 100,000 urine samples.
This task is being facilitated by the development ofcomputer-
ized data collection methods that can handle the accumulation of
large numbers of laboratory samples. For example, for our
studies, stafffrom the epidemiology and endocrinology groups
have worked together to develop a bar-code-readable labeling
and tracking system to facilitate storage and retrieval ofthe large
volume of samples anticipated. This is a new area for both
members ofthe team; epidemiologists are used to hanling large
volumes of questionnaires but not usually laboratory samples.
The epidemiologist must be willing to adapt field methods and
even questionnaires to the demands ofthe assay. For example, for
the Wmen's Reproductive Health Study, the endocrinologist has
specified volume and frequency ofsample collection, amount of
sample collected, and the protocol for storage and transport of
samples.
Others in the field (both assay developers and assay users) must
also be willing to collaborate in order to standardize both lab-
oratory and field methods so that results from multiple studies
are comparable.
Conclusion
Under these conditions, the union ofthe laboratory assay with
the epidemiological study can be very fruitful, with benefits,
both expected and unexpected, to the epidemiologist and the
assay developer.
Epidemiologists turned to studies of early pregnancy loss in
order to a) detect early losses, which may be etiologically dif-
ferent from later losses; b) increase study power (in any fixed
sample size) by increasing the number ofmeasurable pregnan-
cy losses; c) minimize misclassification ofthese outcomes; and
d) decrease selection bias. All ofthese aims are likely to be met
in ourjoint effort. It is likely that the measurable rate ofpregnan-
cy loss will be about three times higher in these studies than that
observable without the use of hormone assays (14). Clearly,
pregnancy losses definedby assay ofbiological samples will have
much greater precision than if studied only through medical
records or self-report. Studies conducted using chemical assay
of biological samples should not be subject to selection bias,
since the outcomes can be determined blindly both for the sub-
ject and the researcher.
In addition, we hope to learn about new health end points that
might not be studied otherwise. Since this collaboration has
begun, it has become clear that reproductive parameters, such
as luteal phase abnormalities, anovulation, and decreased hor-
mone levels, can be studied in addition to early pregnancy loss.
These additional parameters may turn out to be even more useful
and could not have been studied in large populations in the
absence of urinary steroid assays.
The assay developer tuned to epidemiology in order to under-
stand the profile (mean, range, variability) ofthe assay in general
populations. This information is necessary in order that clinical
data in selected populations be properly interpreted. Our recent
collaborative efforts should provide this information.
Additionally, through collaboration with the epidemiologist,
the assay developer learns to think about the population rather
than just the individual. In fact, the "unit of observation" has
changed for the endocrinologists working on the Women's
Reproductive Health Study. While individual samples were the
unit ofobservation in the past, the endocrinologists now view the
entire menstual cycle as the unit of observation.
For researchers from both disciplines, data resultng from such
a collaborative study will be more easily interpretable; biological
mechanisms involved in any observed association should be
clearer to the epidemiologist, and clinical abnormalities should
be more understandable to the endocrinologist in the context of
background rates.
The process ofcollaboration which our work on the Women's
Reproductive Health Study has required, even prior to comple-
tion ofdata collection, has altered our hinindng in profound ways.
For example, prior to this collaboration, both disciplines viewed
conception as an "all or nothing" phenomenon. It was a standing
joke that you could not be "a little bit pregnant:" With increased
understanding by the epidemiologist ofthe subtleties involved in
classifying cycles as "conception" or "nonconception" and an
awareness by the endocrinologist of the power of probability
dteory to deal with such uncertainty, we now speak about the pro-
bability of conception in a given cycle. In fact, we are now
allowing for a tfird alternative in our model, that ofbeing "a little
bit pregnant."
The principles discussed could equally well apply to assays
detecting other markers ofdisease (e.g., DNA damage or sperm
abnormalities) or markers of exposure (e.g., saliva assays for
cotinine, nicotine, and caffeine). This kind ofcollaborative effort
is likely to be ofparticular benefit to environmental epidemiol-
ogy. In the past, environmental studies have often been weak
because of poor assessment of exposure and outcome, both of
which are often self-reported. The use ofbiomarkers provide a
means ofsharpening the tools available to epidemiologists. At the
same time, it provides a population-based context in which
researchers in the laboratory can interpret their assays. We look
forward to continued fruitful collaboration ofbenefit to both the
assay developer and the assay user.
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